Hairy cell leukemia (HCL) is characterized by underexpression of the intracellular signaling molecule RhoH. Reconstitution of RhoH expression limits HCL pathogenesis in a mouse model, indicating this could represent a new therapeutic strategy. However, while RhoH reconstitution is theoretically possible as a therapy, it is technically immensely challenging as an appropriately functional RhoH protein needs to be specifically targeted. Because of this problem, we sought to identify druggable proteins on the HCL surface that were dependent upon RhoH underexpression. One such protein was identified as CD38. Analysis of 51 HCL patients demonstrated that 18 were CD38-positive. Interrogation of the clinical record of 23 relapsed HCL patients demonstrated those that were CD38-positive had a mean time to salvage therapy 71 months shorter than patients who were CD38-negative. Knockout of the CD38 gene in HCL cells increased apoptosis, inhibited adherence to endothelial monolayers, and compromised ability to produce tumors in vivo. Furthermore, an anti-CD38 antibody proved effective against pre-existing HCL tumors. Taken together, our data indicate that CD38 expression in HCL drives poor prognosis by promoting survival and heterotypic adhesion. Our data also indicate that CD38-positive HCL patients might benefit from treatments based on CD38 targeting. Cancer Res; 75(18); 3902-11. Ó2015 AACR.
Introduction
Hairy cell leukemia (HCL) is an indolent lymphoproliferative disease characterized by pancytopenia, hepatomegaly, splenomegaly, leukocytosis, and neoplastic mononuclear cells in the peripheral blood, bone marrow, liver, and spleen (1) . Complete remission rates approaching 95% can be achieved by front-line treatment with the purine nucleoside analogues pentostatin or cladribine and second-line treatments that include rituximab or vemurafenib (2, 3) . However, despite these impressive statistics, a significant proportion of HCL patients either fail to respond to therapy or develop resistant disease (3) . In addition, approximately 48% of patients relapse within 15 years, and as time progresses, the incidence of relapse increases (4) . Because HCL usually presents in late middle-age, countries with aging populations can expect an increasing need for new treatments.
One of the diagnostic markers of HCL is abnormal expression of the gene encoding CD11c (5) . Normally, this gene is transcribed only in cells of the myeloid lineage (6) . However, in HCL, it is also transcribed in the neoplastic lymphocytes. This aberrant transcription is driven by constitutive binding of the proto-oncogene JunD to the CD11c gene promoter (7) . Tracking back along a cascade of molecular events, we demonstrated that this activation of JunD is caused by constitutive signaling through the intracellular Ras pathway (7) .
Signaling by members of the Ras super-family has been shown to be inhibited by high quantitative levels of RhoH (8) . We have found that HCL is characterized by chronic underexpression of RhoH (9). Consequently, the low level of RhoH found in HCL likely allows members of Ras family to be active and drive disease pathogenesis. In vitro reconstitution of RhoH expression inhibits the aberrant expression of CD11c as well as the adhesion and transendothelial migration that are hallmarks of HCL (9) . In a xenograft mouse model, RhoH reconstitution severely limits HCL pathogenesis and protects against mortality (9) .
Our preclinical studies indicate that RhoH reconstitution could be a new therapy for HCL. However, the transition of this therapy from the laboratory bench to the hospital bedside is technically extremely difficult. First, it requires a recombinant protein to be introduced inside hairy cells. Second, it requires this protein to be specifically targeted only to hairy cells. Third, it requires the protein to be functionally and appropriately active when inside the cells. Because of these challenges, a protein was sought that was dependent upon RhoH underexpression but produced on the cell surface and so easily targeted.
In order to identify a cell-surface protein dependent upon RhoH underexpression, we utilized differential microarray analysis to compare the transcriptome of HCL reconstituted with RhoH with the transcriptome of nonreconstituted HCL. This analysis indicated that the mRNA encoding the cell-surface protein CD38 was dependent upon RhoH underexpression. Subsequently, this dependence was confirmed at the protein level. These findings led us to the hypothesis that CD38 could be involved in the pathogenesis of HCL, and its targeting might be therapeutic. In order to test this hypothesis, we performed functional analyses on HCL where the CD38 gene had been knocked out. These studies indicated that CD38 promotes HCL survival, heterotypic adhesion, and the growth of xenografts in mice. That CD38 contributes to HCL pathogenesis was further demonstrated by the finding that CD38-positive patients relapsed dramatically sooner than patients who were CD38-negative. Analysis of 51 HCL patients by flow cytometry or immunohistochemistry demonstrated 18 were CD38-positive. Testing of the humanized anti-CD38 antibody SAR650984 in a mouse model indicates that this approximate one third of HCL patients could benefit from the development of anti-CD38 treatments.
Materials and Methods

Patient material
Immunohistochemical analysis was performed on formalinfixed paraffin-embedded bone marrow biopsies collected from patients diagnosed with either classical HCL or chronic lymphocytic leukemia (CLL) at the Gundersen Medical Center, La Crosse, Wisconsin (10, 11) . The prognostic ability of CD38 was determined by examining the clinical records of 43 patients diagnosed with classical HCL at the Centre Hospitalier Universitaire de Caen, Caen, France. Nine of these patients scored 3 points and 34 patients scored 4 points on the Royal Marsden scoring system for HCL (12) . Cases where multiparameter flow cytometry showed that 30% or more of HCL cells exhibited CD38 expression were designated as being CD38-positive. First-line and salvage treatments were initiated when patients had platelet counts under 100 Â 10 9 /L, hemoglobin levels under 10 g/dL, or an absolute neutrophil count under 1 Â 10 9 /L.
Immunohistochemistry
Formalin-fixed paraffin-embedded blocks containing bone marrow biopsy specimens were serially sectioned at 4 mm and dried overnight on Colorfrost Plus microscope slides (Thermo Fisher Scientific, Inc.). Next, sample slides were deparaffinized, and one slide from each block was stained with hematoxylin and eosin Y. The remaining slides were subjected to epitope retrieval using Epitope Retrieval Solution, pH 9 (Dako North America, Inc.). Next, the slides were rocked with the Peroxidase Blocking reagent of the EnVisionþ System-HRP (DAB; Dako North America, Inc.) and then with Surfact-Amps X-100 (Thermo Fisher Scientific, Inc.). One slide from each block was rocked with an IgG nonimmune rabbit antibody (Epitomics, Inc.). One slide from each block was identically incubated with the rabbit monoclonal antibody EPR4106 that recognizes human CD38 (Abcam, Inc.). Serial rocking incubations were next performed with Labeled Polymer-HRP Anti-Rabbit, Wash Buffer and DABþ Chromogen (Dako North America, Inc.). Finally, slides were counterstained with hematoxylin and the tissue protected by glass coverslips mounted with Permount (Thermo Fisher Scientific, Inc.).
Cell culture
The hairy-cell line HC-1 was obtained from the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ). The hairy-cell line EH was provided by Guy B. Faguet (Veterans Administration Medical Center, Augusta, GA). Subsequently, the real identity of EH was found to be the hairy-cell line HK (13) . Therefore, herein we refer to this line as EH/K. The hairy-cell line ESKOL was provided by Edward F. Srour (Indiana University School of Medicine, Indianapolis, IN). The hairy-cell lines JOK-1 and Hair-M were provided by Jørn Koch (Aarhus University Hospital, Aarhus, Denmark). Human microvascular endothelial cells (HMEC-1) were provided by Laurent Plawinski (CNRS UMS 3408 Universit e de Caen, France). The HCL cell lines JOK-Empty and JOK-RhoH were obtained as previously described and grown in RPMI-1640 containing 10% (v/v) heat-inactivated FBS, 100 units/mL penicillin, 100 mg/mL streptomycin, and 150 mg/mL hygromycin B (Gibco Life Technologies; ref. 9) . All other HCL cell lines were grown in this same medium lacking hygromycin B. HMEC-1 was grown in Medium 131 containing 100 units/mL penicillin, 100 mg/mL streptomycin, and microvascular growth supplement (MVGS; Gibco Life Technologies). In addition, surfaces on which HMEC-1 were grown were coated with attachment factor (Gibco Life Technologies). Activation of HMEC-1 was achieved using 100 ng/mL lipopolysaccharide (LPS; SigmaAldrich).
Generation of stable cell line pools
The plasmid pGL4.51[Luc2/CMV/Neo] contains the luciferase gene of Photinus pyralis under control of the constitutive gene promoter of cytomegalovirus (Promega Corp.). This plasmid was linearized with the restriction endonuclease SalI and transfected into the HCL cell line JOK-1. The cell line pool JOK-Luc was subsequently selected by resistance to 1 mg/mL G418 (SigmaAldrich). Knockout of the CD38 gene was engineered in the HCL cell line JOK-1 using a CompoZR Zinc Finger Nuclease (ZFN) kit (CKOZFND5725; Sigma-Aldrich). Parental JOK-1 cells were transfected with each of the two ZFN plasmids in the Kit and CD38-negative cells isolated by a BD FACSAria I cell sorter (Becton Dickinson) using an FITC-labeled mouse anti-human CD38 antibody and an isotype-matched nonimmune FITClabeled antibody (clones IB6 and IS6-11E5.11, respectively; Miltenyi Biotec). CD38-negative cells were isolated as single clones in 96 multiwell culture plates using the autocloning module of the cell sorter. In the same way, CD38-positive clones were isolated from the bulk of transfected parental JOK-1 cells. Next, the CD38 gene in each isolated clone was sequenced through the ZFNtargeted region (Supplementary Fig. S1 ). Six clones were identified that contained homozygous frameshift mutations within the CD38 coding region (Supplementary Fig. S2 ). Six clones were identified that contained no mutations within this same region. All validated clones were first cultured alone, and then 10 6 cells of each were mixed together to produce the cell line pools JOK-CD38-WT and JOK-CD38-KO representing HCL where the CD38 gene is wild-type or mutated, respectively. Expression of CD38 in each of these pools was assessed by Western blotting and flow cytometry (Supplementary Figs. S3 and S4, respectively).
Microarray analysis
The transcriptomes of JOK-RhoH and JOK-Empty were compared as previously described using Human Whole Genome Quantitative RT-PCR Total RNA from cell cultures was purified and then reversetranscribed into cDNA using Moloney murine lentivirus reverse transcriptase and random primers (Invitrogen, Life Technologies, Corp.; refs. 9, 14). Next, 100 ng of the generated cDNA was subjected to quantitative PCR using the Taqman Universal Master Mix and the CD38 Gene Expression Assay Hs01120068_m1 containing a CD38-specific TaqMan probe and primers (Applied Biosystems, Life Technologies). Linear regression curves constructed using serial dilutions of cDNA generated from the CD38-positive cell line HC-1 quantified CD38 expression levels, which were then normalized against expression of ABL mRNA (9, 14) . PCR was performed on a 7900HT Real-Time PCR System using the standard protocol of SDS 2.4 software (Applied Biosystems, Life Technologies).
Western blotting
Proteins were isolated from cell cultures using the M-PER lysis reagent (Thermo Fisher Scientific, Perbio Science). Proteins were then reduced using sample reducing agent (Life Technologies), subjected to polyacrylamide gel electrophoresis and transferred to nitrocellulose filters. Next, filters were incubated with primary antibodies directed against human CD38, b-actin, or glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Specifically, the anti-CD38 antibody used was mouse monoclonal 22/CD38 (BD Pharmingen). Anti-b-actin was mouse monoclonal AC-15 (Sigma-Aldrich). Anti-GAPDH was rabbit polyclonal FL-335 (Santa Cruz Biotechnology, Inc.). Following incubation with primary antibodies, filters were washed and incubated with appropriate anti-mouse or antirabbit secondary antibodies conjugated with horseradish peroxidase (HRP; Cell Signaling Technology, Inc., Ozyme). Filters were again washed and HRP visualized using the Amersham Analysis was performed using an FITC-conjugated antibody that specifically binds CD38 (CD38 Ab) or an isotype-matched control antibody (Isotype Ab). A representative example of the flow patterns acquired is depicted along with the mean percentages of FITC-positive cells calculated from four experiments AE SD. After subtraction of the fluorescence intensity attributable to the control antibody, the mean fluorescence intensity attributable specifically to the CD38 antibody was 71.8 AE 14.3 SD for JOK-Empty and significantly less at 19.7 AE 9.0 SD for JOK-RhoH (paired Student t test, P ¼ 0.0006). 
Flow cytometry
Flow cytometric analysis of JOK-Empty, JOK-RhoH, JOK-CD38-WT, and JOK-CD38-KO was performed by incubating 5 Â 10 5 cells with a FITC-conjugated version of the monoclonal antibody IB6 directed against CD38 (Miltenyi Biotec). The isotype-matched control for these experiments utilized a FITC-conjugated version of the IgG2b clone IS6-11E5.11 (Miltenyi Biotec). Following incubation with antibodies, cells were analyzed using a CyAn ADP flow cytometer equipped with Summit software 4.3 (Beckman Coulter, Inc.).
Cell-cycle assays
The percentage of cells in the S phase of the cell cycle was assessed using the Click-iT EdU Alexa Fluor 647 Flow Cytometry Assay Kit (Life Technologies). The assay consisted of labeling 5 Â 10 5 cells with 10 mmol/L of 5-ethynyl-2 0 -deoxyuridine (EdU), fixation with Click-iT fixative then permeabilization with Click-iT saponin-based reagent. Next, intracellular EdU was conjugated with Alexa Fluor 647 using the Click-iT reaction cocktail. The percentage of cells that were positive for EdU-Alexa Fluor 647 was determined by flow cytometry and taken as representing the proportion of the culture in S phase.
Apoptosis assays
Cultures of JOK-CD38-WT or JOK-CD38-KO were initiated. After 72 hours, 5 Â 10 5 cells were washed in ice-cold PBS and then incubated with FITC-conjugated Annexin V and propidium iodide (PI; Beckman Coulter, Inc.). The percentage of PI-positive cells that were also Annexin V-positive was determined by flow cytometry and taken as the proportion of the cultures that were undergoing apoptosis.
Heterotypic adhesion assays
The ability of JOK-CD38-WT or JOK-CD38-KO to adhere to HMEC-1 was assessed as previously described (9) . Briefly, monolayers of HMEC-1 were produced in 96 multiwell tissue culture plates and either activated with 100 ng/mL of LPS or left untreated. JOK-CD38-WT or JOK-CD38-KO cultures were incubated with 5 mmol/L BCECF-AM (Life Technologies), washed, then 10 5 of these labeled cells set onto the monolayers. Adhesion was allowed for 1 hour at 37 C, then monolayers were washed and fluorescence intensity measured at 535 nm using a SpectraMax i3 Multi-Mode Detection Platform (Molecular Devices, LLC). All values were corrected by subtraction of the fluorescence intensity of monolayers incubated with wash buffer alone. These corrected values were then plotted against standard curves of fluorescence intensity constructed from serial dilutions of a known number of the corresponding HCL cell line labeled with BCECF-AM. CD38 is differentially expressed by HCL cell lines and patients. A, Western blot analysis of total protein lysates showing that CD38 is expressed by the HCL cell lines JOK-1, HC-1, Hair-M, and Eskol but not the HCL cell line EH/K. An antibody against GAPDH was used in the control analysis of lysates. B, immunohistochemical analysis of CD38 expression in bone marrow biopsies taken from HCL and CLL patients. Eight HCL patients were examined in this way and two found to be CD38-positive. The analysis of one of these CD38-positive patients is depicted (a). The analysis of one of the six HCL patients determined to be CD38-negative is depicted (b). As a control for the analysis of HCL patients, bone marrow biopsies taken from two CLL patients were identically examined for CD38 expression. The diagnostic pathology record of one of these CLL patients indicated that the bone marrow was CD38-positive (c). The pathology record of the second CLL patient indicated the bone marrow was CD38-negative (d). All images were taken at a magnification of Â100.
Mouse husbandry
Mice utilized for subcutaneous xenografts of HCL were housed in sterilized GM500 ventilated cages on a Green Line rack (Techniplast France S.A.). This housing system was kept in a barrier room accredited by the Direction D epartementale de la Protection des Populations du Nord. Mice were monitored daily, and sterile water and Rat & Souris N o 1 Entretien diet (SDS Special Diet Services France, Argenteuil) were provided ad libitum. Mice utilized for intraperitoneal xenografts of HCL were housed in sterilized Super Mouse 750 Micro-Isolator ventilated cages on an RAIR Isosytem rack (Lab Products, Inc.). This housing system was kept in a barrier room accredited by AAALAC-I. Mice were monitored daily, and sterile water and Teklad Global 18% Protein Rodent Diet (Harlan Laboratories, Inc) were provided ad libitum.
Xenograft mouse models
The role of CD38 in HCL was assessed using 5 Â 10 6 of the cell line pools JOK-CD38-WT or JOK-CD38-KO injected subcutaneously into male or female mice that were 6 to 8 weeks old and of the strain NOD.Cg-Prkdc scid IL2rg tm1Wjl /SzJ (Jackson Laboratory). Four weeks after injection, mice were sacrificed and tumors dissected, weighed, and measured with an electronic caliper. Tumor volumes were calculated according to the formula:
, where L is the length, W is the width, and T is the thickness. The therapeutic efficacy of targeting CD38 was assessed using 4 Â 10 6 of the cell line pool JOK-Luc injected into the peritoneum of female mice that were 3 to 4 weeks old and of the strain Hsd:Athymic Nude-Foxn1 nu (Harlan Laboratories, Inc.). After 3 days, mice were anesthetized and injected intravenously with 150 mL of Dulbecco's Phosphate Buffered Saline containing 15 mg/mL D-Luciferin potassium salt (Regis Technologies, Inc.). Superimposed luminescence and X-ray images were acquired using a MS FX PRO In Vivo Imaging System (Bruker Corp.). The day after imaging, mice with visible tumors were injected intraperitoneally with 120 mL of PBS containing 1 mg/mL of either the humanized anti-CD38 antibody SAR650984 (Sanofi Oncology) or a nonimmune IgG1 kappa antibody purified from human myeloma plasma (Sigma-Aldrich). Two days later, the antibody injections were repeated and the following day mice were again imaged. Intraperitoneal xenograft protocols were approved by the Institutional Animal Care and Use Committee of the University of Wisconsin, La Crosse, Wisconsin. Subcutaneous xenograft protocols were approved by the Animal Care Ethical Committee, Nord-Pas-de-Calais, France.
Results
CD38 expression in HCL is dependent upon low-level RhoH
In previous studies, we determined that HCL is characterized by underexpression of the intracellular signaling molecule RhoH (9). This low-level expression likely contributes to the pathogenesis of the disease by unleashing Ras signaling that ultimately results in aberrant transcription of the CD11c gene and consequent extravasation of the neoplastic lymphocytes (7, 9) . Reconstitution of RhoH expression ameliorated HCL pathogenesis in a xenograft mouse model (9) . However, transition of this therapeutic approach to the clinic is not likely to be immanent as targeting the reconstitution of an intracellular protein is immensely challenging. Therefore, we sought a readily druggable surface protein that was dependent upon RhoH underexpression. This was achieved using the cell lines JOK-Empty and JOK-RhoH (9). These lines are derived from the HCL cell line JOK-1 and stably express either the parental vector pMEP4 or this same vector encoding RhoH. Comparison of the transcriptomes of these two derivatives by differential microarray analysis demonstrated that the mRNA encoding the surface protein CD38 is expressed in JOK-RhoH at 0.145, the level at which it is expressed in JOK-Empty (P ¼ 0.003). Repression of CD38 mRNA by RhoH reconstitution was confirmed by RT-PCR analysis (Fig. 1A) . Repression of CD38 protein expression was demonstrated by Western blotting (Fig. 1B) . Finally, flow cytometry demonstrated that RhoH reconstitution repressed the surface expression of CD38 (Fig. 1C) . 16 cases that were CD38-positive and the 27 cases that were CD38-negative are plotted separately with dotted and solid lines, respectively. The mean TTNT of the CD38-positive patients was significantly shorter than that of the patients who were CD38-negative (Gehan-Breslow-Wilcoxon test, P ¼ 0.0023). B, Kaplan-Meier plot showing the TTNT only of the 23 patients within the total of 43 analyzed that suffered relapse. CD38-positive and CD38-negative cases are plotted separately with dotted and solid lines, respectively. The mean TTNT of 8 CD38-positive patients was significantly shorter than that of 15 patients who were CD38-negative (Gehan-Breslow-Wilcoxon test, P < 0.0001). Within the CD38-positive group, 4 had first-line therapy with interferon and 4 had first-line therapy with purine analogues. Within the CD38-negative group, 6 were initially treated with interferon and 9 with purine analogues.
CD38 is differentially expressed both by HCL cell lines and HCL patients
The expression of CD38 in HCL beyond JOK-1 was assessed initially by examining a range of different cell lines by Western blotting (Fig. 2A) . Such analysis demonstrated that while the HCL cell lines JOK-1, HC-1, Hair-M, and Eskol are CD38-positive, the HCL line EH/K is negative. This finding of differential expression of CD38 in HCL was confirmed by analysis of HCL patients. Two of 8 HCL patients diagnosed at Gundersen Health Center in the USA exhibited CD38 expression in bone marrow biopsies (Fig.  2B) . In addition, examination of the clinical records of 43 HCL patients diagnosed at the Centre Hospitalier Universitaire de Caen in France revealed 16 were CD38-positive in the bone marrow and/or peripheral blood. Taken together, the results from the USA and France indicate that the neoplastic lymphocytes of approximately one third of HCL patients exhibit CD38 expression. This proportion is consistent with what has been reported for HCL patients in Sweden (15) .
CD38 expression is a marker of poor HCL prognosis
The impact of CD38 expression on clinical course was evaluated by retrospective analysis of the clinical records of the 43 patients diagnosed with classical HCL at the Centre Hospitalier Universitaire de Caen. Specifically, we investigated the time between the end of first-line therapy and the beginning of salvage therapy at first relapse. This interval was designated as the time to next treatment (TTNT). In the 43 cases, it was found that for the 27 patients who were CD38-negative, the average TTNT was 83 months, but for the 16 patients who were CD38-positive, the average TTNT was only 42 months (Fig. 3A) . When we analyzed specifically the 23 of the 43 patients that relapsed, the difference in TTNT between CD38-negative and CD38-positive cases was even more dramatic. Here, the average TTNT of the 15 patients who were CD38-negative was 95 months, but only 24 months for the 8 patients who were CD38-positive (Fig. 3B ).
CD38 expression promotes HCL growth by protecting against apoptosis
Clinical evidence indicates that CD38 expression in HCL correlates with poor prognosis. Next, we sought to determine if CD38 expression represents a driver or a passenger in HCL pathogenesis. This was addressed by utilizing the HCL cell line JOK-1 that is CD38 positive (Figs. 1B and 2A) . Zinc Finger Nuclease technology produced pools of this line that either contained homozygous frame-shift mutations within the CD38 coding region or contained no mutations within this same region ( Supplementary Fig. S2 ). These pools were designated JOK-CD38-KO and JOK-CD38-WT, respectively. Comparison of the two pools demonstrated that 8 days after the initiation of cultures with equal numbers of cells, the number of JOK-CD38-KO cells was 36% fewer than JOK-CD38-WT (Fig. 4A) . The rate at which cells grow in culture represents the sum of the balance between cell division and cell death. Therefore, which of these processes accounted for the difference in growth rate of JOK-CD38-KO and JOK-CD38-WT was investigated. Incorporation of 5-ethynyl-2 0 -deoxyuridine demonstrated that in cultures of JOK-CD38-KO, the percentage of cells in the DNA synthesis phase of the cell cycle was not significantly different than that in cultures of JOK-CD38-WT (Fig. 4B) . Consequently, CD38 expression appears not to influence HCL proliferation in vitro. However, in contrast, when apoptosis was assessed by cellsurface binding of Annexin V and DNA accessibility to PI, the intrinsic apoptosis rate of JOK-CD38-KO after 72 hours of culture was found to be approximately one third higher than JOK-CD38-WT (Fig. 4C) . Therefore, CD38 expression appears to enhance HCL growth not by effecting an increase in proliferation, but rather by increasing cell survival.
CD38 expression promotes HCL adhesion
The adhesion of T cells and CLL B lymphocytes to endothelial cells has previously been shown to be mediated by CD38 (16, 17) . Therefore, we investigated the possibility that CD38 also contributes to the adhesive properties of HCL B lymphocytes. Confluent monolayers of human microvascular endothelial cells were prepared and either activated with LPS or left untreated. The ability of JOK-CD38-KO and JOK-CD38-WT to adhere to these monolayers was then assessed (Fig. 5 ). This analysis demonstrated that JOK-CD38-KO was 34% less able to bind nonactivated endothelial cells than JOK-CD38-WT and 39% less able to bind activated endothelial cells.
CD38 effects growth of HCL tumors in vivo
Analyses performed in vitro indicate that CD38 drives HCL survival and adhesion (Figs. 4C and 5 ). These results suggest CD38 expression may contribute to the pathogenesis of HCL in vivo. Therefore, to address this question, JOK-CD38-WT and JOK-CD38-KO were injected subcutaneously into immunodeficient mice. After 4 weeks, the resulting tumors were dissected, weighed, and their dimensions measured. This analysis demonstrated that the tumors originating from JOK-CD38-KO had volumes that were on average 40% smaller than those originating from JOK-CD38-WT (Fig. 6A) . In addition, tumor weight was reduced on average by 43% (Fig. 6B) . Therefore, these results support the hypothesis that CD38 influences HCL pathogenesis in vivo.
Targeting CD38 regresses pre-existing HCL tumors in vivo
Experiments performed with JOK-CD38-KO indicate that targeting CD38 expression in HCL may have therapeutic efficacy. This was tested using the parent of JOK-CD38-KO where CD38 expression remained intact. The parental line was engineered such that it constitutively produced luciferase and, therefore, could be visualized by luminescence in the presence of luciferin. This line was then injected into the peritoneum of immunodeficient mice and allowed to form tumors. These tumors were then treated with either a nonimmune control antibody or the anti-CD38 antibody SAR650984 (18) . Luminescence imaging demonstrated that tumors tended to continue to grow after treatment with the control antibody but tended to be reduced by treatment with SAR650984 (Fig. 7) .
Discussion
HCL is an indolent neoplasm predominantly of cells with a genetic signature related to memory B lymphocytes (1, 19) . A stubborn percentage of HCL cases are either resistant to available treatments or relapse with intractable disease (3, 4) . HCL usually presents in late middle age. Therefore, in regions of the world such as North America and Western Europe with a babyboom generation reaching retirement, the absolute number of HCL patients in need of novel treatments is set to increase. Here, we report for the first time that targeting CD38 could represent one such novel therapy. We find that approximately one third of HCL patients exhibit CD38 expression, and that this expression correlates with poor prognosis. Evidence developed in vitro indicates that the molecular basis of this heightened pathogenesis is the ability of CD38 to effect increased lymphocyte survival and an increased ability to bind endothelium.
The natural history of CD38 expression in HCL bears a striking resemblance to that in CLL. Both are indolent neoplasms with phenotypes related to memory B cells (19) (20) (21) . Approximately one third of both HCL and CLL patients are CD38-positive when the cutoff for positivity is set at 30% of the malignant clone Cancer Research (22) (23) (24) . In both HCL and CLL, CD38 mediates adhesion to endothelial cells (16, 17) . In both HCL and CLL, CD38 protects against apoptosis (25, 26) . In both HCL and CLL, CD38 positivity is a negative prognostic indicator (22, 24, (27) (28) (29) (30) (31) .
It is now widely accepted that in CLL there are dynamic shifts of neoplastic cells between the blood stream and lymphoid tissue. In the circulation, CLL cells manifest resistance to apoptosis, but are compromised in their ability to proliferate while in lymphoid tissue they are susceptible to apoptosis or induced to proliferate (32) (33) (34) (35) . These findings indicate that the microenvironment of lymphoid tissue is necessary for CLL proliferation but not for apoptosis resistance (36) . CD38 has been implicated in mediating both microenvironment-dependent CLL proliferation and microenvironment-independent survival (16, 37, 38) . Extrapolating these roles of CD38 from CLL to HCL would provide an explanation for our observation that knockout of the CD38 gene fails to influence cell division in HCL monocultures but does compromise survival.
In addition to CLL, CD38 has previously been found to be expressed in a wide range of other hematologic malignancies, including B-cell and T-cell acute lymphoblastic leukemia, multiple myeloma, B-cell non-Hodgkin's lymphoma, and acute myeloid leukemia (39) (40) (41) (42) . Targeting CD38 in xenograft models of these malignancies has been demonstrated to have therapeutic efficacy, and trials are currently under way to determine clinical utility (43) (44) (45) (46) (47) (48) (49) (50) . The results reported here indicate that HCL should be added to the list of blood cancers where anti-CD38 therapy is being evaluated. However, because monotherapy often results in the evolution of resistant disease, combining CD38 targeting with existing HCL treatments such as purine analogues and agents that target CD20 and B-Raf might prove particularly beneficial. mice were subjected to whole body imaging following intravenous injection of D-Luciferin. Those mice where tumor was detected were intraperitoneally injected at day 4 and day 6 with the anti-CD38 antibody SAR650984 or an IgG control antibody. At day 7, mice were again imaged. Depicted are superimposed luminescence and X-ray images of three mice injected with SAR650984 (CD38) and three injected with the control antibody (Ctrl).
